eligibility_summary
Eligible adults 19–74 with DLBCL, PMBCL, high-grade B-cell lymphoma, or Burkitt lymphoma diagnosed after Jan 2015, who received immunochemotherapy for relapsed/refractory disease. Excludes those progressed to acute leukemia, who developed a solid tumor during treatment, or with active infections (e.g., pneumonia, viral infection, active hepatitis B, active tuberculosis).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational study in relapsed/refractory high‑grade B‑cell lymphomas comparing advanced vs classical immunochemotherapy. Advanced: CAR‑T therapy (autologous engineered T cells with CARs to B‑cell antigens, typically CD19/CD20, targeted T‑cell cytotoxicity), bispecific antibodies (off‑the‑shelf T‑cell–redirecting dual binders, commonly CD3×CD20, activate T cells to kill B cells), antibody‑drug conjugates (mAb plus cytotoxic payload delivering drug to antigen‑positive B cells). Classical: monoclonal antibodies (anti‑CD20 such as rituximab/obinutuzumab, ADCC/CDC, apoptosis), proteasome inhibitors (e.g., bortezomib, carfilzomib, inhibit 26S proteasome, disrupt NF‑κB/proteostasis to induce apoptosis), IMiDs (e.g., lenalidomide, thalidomide, enhance T/NK activity, immune modulation). Targets/pathways: malignant B cells (CD19/CD20), T/NK activation, complement/ADCC, proteasome/NF‑κB.